Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(17%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_3
3
50%
Ph phase_2
1
17%
Ph not_applicable
1
17%
Ph phase_4
1
17%

Phase Distribution

0

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
3(50.0%)
Phase 4Post-market surveillance
1(16.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(2)
Other(2)

Detailed Status

Completed2
unknown2
Enrolling by invitation1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (16.7%)
Phase 33 (50.0%)
Phase 41 (16.7%)
N/A1 (16.7%)

Trials by Status

enrolling_by_invitation117%
recruiting117%
completed233%
unknown233%

Recent Activity

1 active trials
Showing 5 of 6
enrolling_by_invitationphase_2

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

NCT05492578
recruitingphase_3

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

NCT06241118
completedphase_3

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

NCT06224348
completedphase_3

5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

NCT00120523
unknownnot_applicable

NMF-CsA-Dupi Trial

NCT04878770
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05492578Phase 2

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

Enrolling By Invitation
NCT06241118Phase 3

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

Recruiting
NCT06224348Phase 3

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

Completed
NCT00120523Phase 3

5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

Completed
NCT04878770Not Applicable

NMF-CsA-Dupi Trial

Unknown
NCT03461302Phase 4

Efficacy of Topical Coal Tar in Children With Atopic Dermatitis

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6